SG Americas Securities LLC raised its position in Certara, Inc. (NASDAQ:CERT - Free Report) by 350.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 69,727 shares of the company's stock after purchasing an additional 54,235 shares during the quarter. SG Americas Securities LLC's holdings in Certara were worth $690,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. ArrowMark Colorado Holdings LLC lifted its position in shares of Certara by 164.2% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 6,213,278 shares of the company's stock worth $66,171,000 after buying an additional 3,861,674 shares during the last quarter. Ameriprise Financial Inc. lifted its position in shares of Certara by 864.0% in the fourth quarter. Ameriprise Financial Inc. now owns 3,779,655 shares of the company's stock worth $40,253,000 after buying an additional 3,387,590 shares during the last quarter. Mackenzie Financial Corp acquired a new stake in shares of Certara in the fourth quarter worth about $17,852,000. Brown Brothers Harriman & Co. lifted its position in shares of Certara by 63.8% in the fourth quarter. Brown Brothers Harriman & Co. now owns 3,818,613 shares of the company's stock worth $40,668,000 after buying an additional 1,487,998 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of Certara by 169.0% in the fourth quarter. Bank of New York Mellon Corp now owns 1,995,071 shares of the company's stock worth $21,248,000 after buying an additional 1,253,385 shares during the last quarter. Hedge funds and other institutional investors own 73.96% of the company's stock.
Certara Price Performance
CERT stock opened at $10.54 on Friday. The stock has a 50-day moving average price of $12.24 and a two-hundred day moving average price of $11.85. The stock has a market cap of $1.71 billion, a PE ratio of -527.00 and a beta of 1.44. The company has a current ratio of 2.78, a quick ratio of 2.78 and a debt-to-equity ratio of 0.27. Certara, Inc. has a 1 year low of $8.64 and a 1 year high of $16.93.
Certara (NASDAQ:CERT - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.10 by $0.04. The company had revenue of $106.00 million during the quarter, compared to analysts' expectations of $104.44 million. Certara had a positive return on equity of 5.05% and a negative net margin of 0.67%. Certara's revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.10 EPS. Equities analysts forecast that Certara, Inc. will post 0.28 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
CERT has been the subject of several research analyst reports. Robert W. Baird boosted their price objective on Certara from $9.00 to $13.00 and gave the stock a "neutral" rating in a research report on Friday, April 11th. Barclays raised Certara from an "equal weight" rating to an "overweight" rating and boosted their price objective for the stock from $11.00 to $14.00 in a research report on Thursday, May 8th. TD Cowen initiated coverage on Certara in a research report on Thursday, February 27th. They set a "buy" rating and a $16.00 price objective for the company. JMP Securities reissued a "market perform" rating on shares of Certara in a research report on Tuesday, May 6th. Finally, William Blair reissued a "market perform" rating on shares of Certara in a research report on Thursday, February 27th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $15.67.
Check Out Our Latest Analysis on Certara
Certara Profile
(
Free Report)
Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Certara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Certara wasn't on the list.
While Certara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
